Abstract P231: Prevalence Of Comorbid Hypertension Among Hospitalized Patients With Cancer: Results From U.s. Population-based Inpatient Database

Abstract

Background: Hypertension (HTN) is the most common comorbidity in patients with cancer. Age and race/ethnicity affect the morbidity and mortality of HTN and cancer. We investigated the status of comorbid HTN stratified by age and race/ethnicity among hospitalized patients with cancer in the U.S. Methods: Using 2016-2018 National Inpatient Sample data, we included hospitalized adults with a primary diagnosis of cancer and classified them by diagnosis of HTN. Patients were further grouped by age (18-54, 55-64, 65-74, 75+ years), race/ethnicity (white, black, Hispanic, Asian, and others). The top 12 most common cancers were selected, including kidney cancer. Multivariate logistic regression was used to obtain the odds ratios (ORs) and the predicted percentages of HTN by cancer type, age, and race/ethnicity. Results: Among 956,601 hospitalized cancer patients, 56.4% (n=539,978) had HTN. The mean age was 64.5 (SE=0.068) years, and 70.4% (n=673,640) was white patients. The predicted percentages of having HTN were higher in black (67.5%, OR=2.02, p<0.001), Hispanic (56.0%, OR=1.08, p<0.001), and Asian (57.0%, OR=1.14, p<0.001) patients than white patients (54.5%). Compared to patients aged 18-54 years (41.4%), the percentages of having HTN were higher in those aged 55-64 (55.1%, OR=1.98, p<0.001), those aged 65-74 (60.4%, OR=2.57, p<0.001) and those aged 75+ (67.6%, OR=3.73, p<0.001). The percentages of HTN were the highest in kidney cancer patients across all age and race/ethnicity groups (Table). Conclusions: HTN is highly prevalent among hospitalized cancer patients, especially kidney cancer. This study provides evidence for improving care in patients with cancer and HTN.